## George Giannakoulas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1192932/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations. Acta Cardiologica, 2022, 77, 1-13.	0.9	5
2	Atrial High-Rate Episodes in Patients with Devices Without a History of Atrial Fibrillation: a Systematic Review and Meta-analysis. Cardiovascular Drugs and Therapy, 2022, 36, 951-958.	2.6	7
3	Estimation of the economic burden of atrial fibrillation-related stroke in Greece. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 429-435.	1.4	3
4	Indications for percutaneous left atrial appendage occlusion in hospitalized patients with atrial fibrillation. Journal of Cardiovascular Medicine, 2022, 23, 176-182.	1.5	7
5	Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Hellenic Journal of Cardiology, 2022, 64, 93-96.	1.0	7
6	The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors. Expert Opinion on Pharmacotherapy, 2022, 23, 321-325.	1.8	7
7	Modification Tadalafil and Macitentan tablets to aerosol. Frontiers in Bioscience, 2022, 27, 1.	2.1	0
8	Associations of Atrial Fibrillation Patterns With Mortality and Cardiovascular Events: Implications of the MISOAC-AF Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842110694.	2.0	2
9	Haemoptysis in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights on Pathophysiology, Diagnosis and Management. Journal of Clinical Medicine, 2022, 11, 633.	2.4	6
10	Prevalence of markers of atrial cardiomyopathy in embolic stroke of undetermined source: A systematic review. European Journal of Internal Medicine, 2022, 99, 38-44.	2.2	12
11	Role of cardiac CT in the diagnostic evaluation and risk stratification of patients with myocardial infarction and non-obstructive coronary arteries (MINOCA): rationale and design of the MINOCA-GR study. BMJ Open, 2022, 12, e054698.	1.9	8
12	The bidirectional relationship of thyroid disease and atrial fibrillation: Established knowledge and future considerations. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 621-630.	5.7	8
13	Advances in treatment of chronic thromboembolic pulmonary hypertension. Thrombosis Research, 2022, 212, 30-37.	1.7	3
14	CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2022, 16, 272-276.	1.5	8
15	Anticoagulation for atrial fibrillation in active cancer (Review). Oncology Letters, 2022, 23, 124.	1.8	6
16	P-wave dispersion as a marker of atrial cardiopathy in embolic stroke of undetermined source. Author's reply European Journal of Internal Medicine, 2022, , .	2.2	1
17	Autonomic Neuromodulation for Atrial Fibrillation Following Cardiac Surgery. Journal of the American College of Cardiology, 2022, 79, 682-694.	2.8	15
18	The Adult Congenital Heart Disease Anatomic and Physiological Classification: Associations with Clinical Outcomes in Patients with Atrial Arrhythmias. Diagnostics, 2022, 12, 466.	2.6	4

#	Article	IF	CITATIONS
19	Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation. Cardiovascular Diabetology, 2022, 21, 39.	6.8	19
20	Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum. Hellenic Journal of Cardiology, 2022, 66, 32-40.	1.0	2
21	Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL. Reviews in Cardiovascular Medicine, 2022, 23, 081.	1.4	3
22	Eisenmenger Syndrome. Journal of the American College of Cardiology, 2022, 79, 1183-1198.	2.8	19
23	Education level predicts mortality and morbidity in hospitalised patients with atrial fibrillation. Hellenic Journal of Cardiology, 2022, , .	1.0	0
24	Temporal trends in the efficacy of revascularization in stable ischaemic heart disease: a cumulative meta-analysis American Journal of Preventive Cardiology, 2022, 10, 100340.	3.0	0
25	Elevated red cell distribution width and cardiovascular mortality in ASCVD risk cohorts: National Health and Nutrition Examination Survey (NHANES III). Reviews in Cardiovascular Medicine, 2022, 23, 051.	1.4	3
26	Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension in Greece: Data from the Hellenic Pulmonary Hypertension Registry. Journal of Clinical Medicine, 2022, 11, 2211.	2.4	6
27	Comparative efficacy and safety of oral P2Y <sub>12</sub> inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis. Open Heart, 2022, 9, e001937.	2.3	2
28	Cardiotoxicity of Azithromycin in COVID-19: An Overall Proportion Meta-Analysis. Advances in Respiratory Medicine, 2022, 90, 171-182.	1.0	3
29	The impact of cardiovascular comorbidities associated with risk for left heart disease on idiopathic pulmonary arterial hypertension: Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Pulmonary Circulation, 2022, 12, .	1.7	4
30	Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease. Cardiovascular Diabetology, 2022, 21, 70.	6.8	18
31	Successful bronchial artery embolization in a patient with Eisenmenger syndrome and recurrent haemoptysis. International Journal of Cardiology Congenital Heart Disease, 2022, , 100386.	0.4	0
32	Atherosclerosis in Congenital HeartÂDisease. , 2022, 1, 100035.		1
33	Portopulmonary Hypertension: A Review of the Current Literature. Heart Lung and Circulation, 2022, ,	0.4	4
34	Right Ventricular Myocardial Work Characterization in Patients With Pulmonary Hypertension and Relation to Invasive Hemodynamic Parameters and Outcomes. American Journal of Cardiology, 2022, 177, 151-161.	1.6	15
35	Renal function and mortality in patients with atrial fibrillation. Journal of Cardiovascular Medicine, 2022, 23, 430-438.	1.5	6
36	Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f63-f71.	3.0	23

#	Article	IF	CITATIONS
37	Biochemical and imaging markers in patients with thalassaemia. Hellenic Journal of Cardiology, 2021, 62, 4-12.	1.0	4
38	Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2021, 51, 81-88.	2.1	6
39	Myocardial deformation assessment in patients with precapillary pulmonary hypertension: A cardiac magnetic resonance study. Diagnostic and Interventional Imaging, 2021, 102, 153-161.	3.2	8
40	Venous thromboembolism in the era of COVID-19. Phlebology, 2021, 36, 91-99.	1.2	22
41	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
42	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	2.2	971
43	Hospitalizations in adult patients with congenital heart disease: an emerging challenge. Heart Failure Reviews, 2021, 26, 347-353.	3.9	5
44	A novel prognostic tool to predict mortality in patients with atrial fibrillation: The BASIC-AF risk score. Hellenic Journal of Cardiology, 2021, 62, 339-348.	1.0	11
45	Prediction of long-term survival in patients with transfusion-dependent hemoglobinopathies: Insights from cardiac imaging and ferritin. Hellenic Journal of Cardiology, 2021, 62, 429-438.	1.0	1
46	Atrial conduction time associated predictors of recurrent atrial fibrillation. International Journal of Cardiovascular Imaging, 2021, 37, 1267-1277.	1.5	4
47	Long-Term Effect of an Exercise Training Program on Physical Functioning and Quality of Life in Pulmonary Hypertension: A Randomized Controlled Trial. BioMed Research International, 2021, 2021, 1-12.	1.9	5
48	Atrial septal defect and pulmonary arterial hypertension. "Treat and repair―or just "treat�. International Journal of Cardiology Congenital Heart Disease, 2021, 2, 100113.	0.4	0
49	Prognostic significance of diabetes mellitus in patients with atrial fibrillation. Cardiovascular Diabetology, 2021, 20, 40.	6.8	26
50	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
51	Adult congenital heart disease: Looking back, moving forward. International Journal of Cardiology Congenital Heart Disease, 2021, 2, 100076.	0.4	4
52	Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology, 2021, 77, 397-407.	1.9	29
53	Chronic hypertension in pregnancy: synthesis of influential guidelines. Journal of Perinatal Medicine, 2021, 49, 859-872.	1.4	14
54	Prediction Models and Scores in Adult Congenital Heart Disease. Current Pharmaceutical Design, 2021, 27, 1232-1244.	1.9	11

#	Article	IF	CITATIONS
55	Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap. Current Pharmaceutical Design, 2021, 27, 1068-1079.	1.9	2
56	Cardiovascular Disease Risk Prediction Models and Scores. Current Pharmaceutical Design, 2021, 27, 1231-1231.	1.9	0
57	Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. Frontiers in Cardiovascular Medicine, 2021, 8, 646064.	2.4	8
58	COVID-19 in Adults With CongenitalÂHeart Disease. Journal of the American College of Cardiology, 2021, 77, 1644-1655.	2.8	55
59	Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial. Atherosclerosis, 2021, 323, 37-43.	0.8	7
60	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease. Hypertension, 2021, 77, 1442-1455.	2.7	22
61	Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2021, 52, 1137-1150.	2.1	5
62	Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases. Rheumatology International, 2021, 41, 1289-1298.	3.0	5
63	Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovascular Drugs and Therapy, 2021, , 1.	2.6	9
64	Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Failure Reviews, 2021, , 1.	3.9	9
65	Is there a role for renin–angiotensin–aldosterone system and neprilysin inhibition in the failing systemic right ventricle?. International Journal of Cardiology Congenital Heart Disease, 2021, 3, 100119.	0.4	1
66	The spectrum of COVID-19 in complex adult congenital heart disease: A case series. International Journal of Cardiology Congenital Heart Disease, 2021, 3, 100097.	0.4	0
67	Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?. Journal of Clinical Medicine, 2021, 10, 2826.	2.4	12
68	Editorial: Patent Foramen Ovale (PFO) Closure for Prevention of Stroke. Frontiers in Neurology, 2021, 12, 718457.	2.4	1
69	Î <b>¤</b> e association of heart failure across left ventricular ejection fraction with mortality in atrial fibrillation. ESC Heart Failure, 2021, 8, 3189-3197.	3.1	3
70	Assessment of biventricular function in patients with hepatopulmonary syndrome. International Journal of Cardiovascular Imaging, 2021, 37, 2891-2900.	1.5	3
71	Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis. Pulmonary Pharmacology and Therapeutics, 2021, 68, 102036.	2.6	4
72	Comparative efficacy and safety of oral P2Y12 inhibitors for patients with chronic kidney disease and acute coronary syndrome: a network meta-analysis. Hellenic Journal of Cardiology, 2021, 63, 40-40.	1.0	1

#	Article	IF	CITATIONS
73	Atrial Fibrillation Is Associated with Cognitive Impairment, All-Cause Dementia, Vascular Dementia, and Alzheimer's Disease: a Systematic Review and Meta-Analysis. Journal of General Internal Medicine, 2021, 36, 3122-3135.	2.6	41
74	History of heart failure hospitalisation predicts mortality in adult congenital heart disease morbidity and mortality in ACHD. International Journal of Cardiology Congenital Heart Disease, 2021, 4, 100191.	0.4	0
75	Peripheral microangiopathy in Eisenmenger syndrome: A nailfold video capillaroscopy study. International Journal of Cardiology, 2021, 336, 54-59.	1.7	7
76	Repeat Coronary Artery Bypass Grafting: A Meta-Analysis of Off-Pump versus On-Pump Techniques in a Large Cohort of Patients. Heart Lung and Circulation, 2021, 30, 1281-1291.	0.4	5
77	Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders, 2021, 21, 453.	1.7	3
78	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	4.6	11
79	Usefulness of acute vasoreactivity testing to decide shunt closure. International Journal of Cardiology Congenital Heart Disease, 2021, , 100228.	0.4	0
80	Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	0
81	Epidemiology and Management of Chronic Thromboembolic Pulmonary Hypertension in Greece. Real-World Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Journal of Clinical Medicine, 2021, 10, 4547.	2.4	8
82	Peripheral microangiopathyÂin precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study. Respiratory Research, 2021, 22, 27.	3.6	20
83	Radiofrequency catheter ablation for ventricular tachycardia in tetralogy of fallot: A systematic review. International Journal of Cardiology Congenital Heart Disease, 2021, 6, 100265.	0.4	2
84	Gestational Hypertension and Preeclampsia: An Overview of National and International Guidelines. Obstetrical and Gynecological Survey, 2021, 76, 613-633.	0.4	28
85	Left Atrial Strain Identifies Increased Atrial Ectopy in Patients with Beta-Thalassemia Major. Diagnostics, 2021, 11, 1.	2.6	47
86	Sarcopenia in heart failure: â€~waste' the appropriate time and resources, not the muscles. European Journal of Preventive Cardiology, 2021, 28, 1019-1021.	1.8	3
87	Frailty in patients undergoing transcatheter aortic valve replacement: from risk scores to frailty-based management. Journal of Geriatric Cardiology, 2021, 18, 479-486.	0.2	1
88	The Interplay between Myocardial Fibrosis, Strain Imaging and Collagen Biomarkers in Adults with Repaired Tetralogy of Fallot. Diagnostics, 2021, 11, 2101.	2.6	4
89	Predictive Role of Platelet-Associated Indices on Admission and Discharge in the Long-Term Prognosis of Acute Coronary Syndrome Patients. Angiology, 2021, , 000331972110521.	1.8	1
90	Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precapillary pulmonary hypertension: A cardiac magnetic resonance study. Hellenic Journal of Cardiology, 2020, 61, 112-117.	1.0	9

#	Article	IF	CITATIONS
91	Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension. Heart Lung and Circulation, 2020, 29, 142-148.	0.4	11
92	Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital. Acta Cardiologica, 2020, 75, 527-534.	0.9	5
93	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
94	Parental alcohol exposure and congenital heart diseases in offspring: A causal link with controversial evidence. European Journal of Preventive Cardiology, 2020, 27, 407-409.	1.8	5
95	Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome. European Journal of Preventive Cardiology, 2020, 27, 2314-2317.	1.8	3
96	Distribution, infrastructure, and expertise of heart failure and cardioâ€oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 3408-3413.	3.1	6
97	Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart, 2020, 106, 1638-1645.	2.9	39
98	<i>Coxiella</i> Endocarditis as the Cause of Recurrent Fever and Brain Abscess in a Patient with Complex Congenital Heart Disease: A Case Report and Literature Review. Case Reports in Infectious Diseases, 2020, 2020, 1-5.	0.5	1
99	Overweight and obesity: time to reconsider their role in heart failure. European Journal of Preventive Cardiology, 2020, 28, 946-947.	1.8	1
100	Association of anticoagulant-related bleeding events with cancer detection in atrial fibrillation: A systematic review and meta-analysis. Hellenic Journal of Cardiology, 2020, 62, 359-365.	1.0	5
101	Adult congenital heart care in the COVID-19 era, and beyond: A call for action. International Journal of Cardiology Congenital Heart Disease, 2020, 1, 100002.	0.4	4
102	Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome. American Journal of Cardiology, 2020, 133, 7-14.	1.6	7
103	Use of Anticoagulants in Patients with Pulmonary Hypertension. Hamostaseologie, 2020, 40, 348-355.	1.9	15
104	Rationale and design of a prospective, observational, multicentre study on the safety and efficacy of apixaban for the prevention of thromboembolism in adults with congenital heart disease and atrial arrhythmias: the PROTECT-AR study. BMJ Open, 2020, 10, e038012.	1.9	5
105	Congenital Heart Disease (CHD): position statement of the Sports Cardiology & amp; Exercise Section of the European Association of Preventive Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and Prevention Working Group of the Association for European Paediatric and Congenital Cardiology	2.2	75
106	(AEPC). European Heart Journal, 2020, 41, 4191-4199. Thrombosis and thromboprophylactic strategies in the adult with Fontan circulation. International Journal of Cardiology Congenital Heart Disease, 2020, 1, 100054.	0.4	2
107	From hybrid techniques to "hybrid―mentality: Modern strategies for perimembranous VSD interventions. International Journal of Cardiology, 2020, 316, 70-71.	1.7	1
108	Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations. ESC Heart Failure, 2020, 7, 1477-1487.	3.1	6

#	Article	IF	CITATIONS
109	The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358.	3.9	15
110	Non-Vitamin K Oral Anticoagulants in Adults with Congenital Heart Disease: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 1794.	2.4	19
111	Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation—the REFLEC-CR Study. Cardiovascular Drugs and Therapy, 2020, 34, 383-389.	2.6	1
112	How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. ESC Heart Failure, 2020, 7, 15-25.	3.1	10
113	Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension. International Journal of Cardiology, 2020, 306, 187-189.	1.7	3
114	Rationale and design of a randomized study comparing Motivational Interviewing to Support Oral Anticoagulation adherence versus usual care in patients with nonvalvular atrial fibrillation: The MISOAC-AF trial. Hellenic Journal of Cardiology, 2020, 61, 453-454.	1.0	20
115	Association Between Atrial Fibrillation and Cognitive Impairment in Individuals With Prior Stroke. Stroke, 2020, 51, 1662-1666.	2.0	21
116	Non-Vitamin K Antagonist Oral Anticoagulants in Pulmonary Embolism: An Overview of Systematic Reviews. Current Pharmaceutical Design, 2020, 26, 2686-2691.	1.9	3
117	Peripheral Microangiopathy in Patients with Precapillary Pulmonary Hypertension: Correlation with Cardiac Function and Patients' Functional Capacity. Study Design and Rationale. Mediterranean Journal of Rheumatology, 2020, 31, 369.	0.8	8
118	Balloon atrial septostomy in severe precapillary pulmonary hypertension: A single-center experience. Hellenic Journal of Cardiology, 2019, 60, 384-386.	1.0	4
119	The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. European Respiratory Journal, 2019, 54, 1901401.	6.7	18
120	Epidemiology and initial management of pulmonary arterial hypertension: realâ€world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Pulmonary Circulation, 2019, 9, 1-12.	1.7	21
121	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
122	A gut feeling about children's exposure to hypertensive disorders of pregnancy in utero. European Journal of Preventive Cardiology, 2019, 26, 1715-1717.	1.8	0
123	Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions. European Journal of Internal Medicine, 2019, 65, 17-25.	2.2	8
124	Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2019, 48, 225-232.	2.1	3
125	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. Current Pharmacology Reports, 2019, 5, 210-213.	3.0	0
126	Physicians' guideline adherence is associated with longâ€ŧerm heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	7.1	86

#	Article	IF	CITATIONS
127	Pregnancy still contraindicated in pulmonary arterial hypertension related to congenital heart disease: True or false?. European Journal of Preventive Cardiology, 2019, 26, 1064-1066.	1.8	7
128	Pulmonary arterial hypertension: the case for a bioelectronic treatment. Bioelectronic Medicine, 2019, 5, 20.	2.3	15
129	Practical Recommendations for the Diagnosis and Medical Management of Stable Angina. Journal of Cardiovascular Pharmacology, 2019, 74, 308-314.	1.9	4
130	Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 225-232.	2.0	14
131	Strength training in congenital heart disease: A way to boost respiratory function?. European Journal of Preventive Cardiology, 2019, 26, 489-491.	1.8	5
132	How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2019, 17, 11-18.	1.5	12
133	Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design. Hellenic Journal of Cardiology, 2019, 60, 249-253.	1.0	9
134	Hospitalisations for heart failure predict mortality in pulmonary hypertension related to congenital heart disease. Heart, 2019, 105, 465-469.	2.9	9
135	Pulmonary Arterial Hypertension in Connective Tissue Disorders: The emerging role of screening and early diagnosis. A position paper for Greek Rheumatologists. Mediterranean Journal of Rheumatology, 2019, 30, 90-93.	0.8	4
136	Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure. European Journal of Heart Failure, 2018, 20, 614-616.	7.1	11
137	A case of sarcoidosisâ€associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-6.	1.7	4
138	The predictive value of baseline pulmonary hypertension in early and long term cardiac and all-cause mortality after transcatheter aortic valve implantation for patients with severe aortic valve stenosis: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 2018, 19, 859-867.	0.8	15
139	Epidemiology and management of chronic thromboembolic pulmonary hypertension: experience from two expert centers. Hellenic Journal of Cardiology, 2018, 59, 16-23.	1.0	12
140	Acquired cardiovascular disease in adult patients with congenital heart disease. Heart, 2018, 104, 546-547.	2.9	10
141	Pregnancy outcome in women with congenital heart disease: A single-center experience. Hellenic Journal of Cardiology, 2018, 59, 155-159.	1.0	29
142	Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovascular Drugs and Therapy, 2018, 32, 617-624.	2.6	46
143	Use of levosimendan in acute heart failure. European Heart Journal Supplements, 2018, 20, I2-I10.	0.1	27
144	Overview of Systematic Reviews of Non–Vitamin K Oral Anticoagulants in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004769.	2.2	21

#	Article	IF	CITATIONS
145	Congenital Heart Disease: Simple Lesions. , 2018, , 767-790.		О
146	Review article: Update on current and emergent data on hepatopulmonary syndrome. World Journal of Gastroenterology, 2018, 24, 1285-1298.	3.3	49
147	Patent Ductus Arteriosus and Aortopulmonary Window. , 2018, , 402-408.		ο
148	Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. Cardiology, 2018, 140, 126-132.	1.4	19
149	Definition and Management of Segmental Pulmonary Hypertension. Journal of the American Heart Association, 2018, 7, .	3.7	41
150	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	2.2	1,396
151	Right Atrial Function Predicts Clinical Outcome in Patients with Precapillary Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2018, 31, 1137-1145.	2.8	12
152	Pulmonary Arterial Hypertension. Congenital Heart Disease in Adolescents and Adults, 2018, , 129-142.	0.2	0
153	Paradoxical bradycardia and blood pressure elevation during dobutamine stress echocardiography reveal ischemia in a patient with syncope. Hellenic Journal of Cardiology, 2017, 58, 291-293.	1.0	1
154	SPECT and PET in ischemic heart failure. Heart Failure Reviews, 2017, 22, 243-261.	3.9	20
155	Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality. Hellenic Journal of Cardiology, 2017, 58, 331-339.	1.0	33
156	Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: Results from the Amplatzer Cardiac Plug registry. International Journal of Cardiology, 2017, 236, 232-236.	1.7	33
157	Methodological Remarks in the Meta-Analysis on the Impact of Baseline Pulmonary Hypertension on Post-Transcatheter Aortic Valve Implantation Outcomes. American Journal of Cardiology, 2017, 120, 513-514.	1.6	2
158	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. International Journal of Cardiology, 2017, 243, 389-395.	1.7	26
159	Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical Drug Investigation, 2017, 37, 833-844.	2.2	13
160	LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND PREVIOUS MAJOR GASTROINTESTINAL BLEEDING: INSIGHT FROM THE AMPLATZER CARDIAC PLUG MULTICENTER REGISTRY. Journal of the American College of Cardiology, 2017, 69, 1139.	2.8	0
161	Pregnancy in Patients With Congenital Heart Disease. Cardiology in Review, 2017, 25, 326-330.	1.4	10
162	Adult congenital heart disease in Greece: Preliminary data from the CHALLENGE registry. International Journal of Cardiology, 2017, 245, 109-113.	1.7	18

#	Article	IF	CITATIONS
163	Novel echocardiographic prognostic markers for cardiac tamponade in patients with large malignant pericardial effusions: A paradigm shift from flow to tissue imaging. Echocardiography, 2017, 34, 1315-1323.	0.9	4
164	PAH in ACHD: Research, Global Perspective and Future Prospects. An Epilogue. Congenital Heart Disease in Adolescents and Adults, 2017, , 363-368.	0.2	0
165	A case of balloon pulmonary angioplasty as a palliative therapy in chronic thromboembolic pulmonary hypertension. Hellenic Journal of Cardiology, 2016, 57, 363-365.	1.0	3
166	Adult congenital heart disease: A paradigm of epidemiological change. International Journal of Cardiology, 2016, 218, 269-274.	1.7	79
167	Pulmonary arterial hypertension in congenital heart disease: Current perspectives and future challenges. Hellenic Journal of Cardiology, 2016, 57, 218-222.	1.0	29
168	Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?. Nephrology Dialysis Transplantation, 2016, 32, gfw345.	0.7	15
169	Atrial septostomy and disease targeting therapy in pulmonary hypertension secondary to neurofibromatosis. BMC Pulmonary Medicine, 2016, 16, 175.	2.0	7
170	Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?. Cardiology, 2016, 134, 311-319.	1.4	633
171	Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 516-525.	2.0	6
172	Aortic balloon valvuloplasty before transcatheter valve replacement in high-risk patients with aortic stenosis. Herz, 2016, 41, 144-150.	1.1	4
173	Imaging of congenital heart disease in adults. European Heart Journal, 2016, 37, 1182-1195.	2.2	68
174	Hepatopulmonary syndrome is associated with the presence of hepatocellular carcinoma in patients with decompensated cirrhosis. Annals of Gastroenterology, 2016, 30, 225-231.	0.6	6
175	Intra - and Intercellular Calcium Handling in Pulmonary Arterial Hypertension. Medicinal Chemistry, 2016, 12, 162-169.	1.5	6
176	Medical students' satisfaction with the Applied Basic Clinical Seminar with Scenarios for Students, a novel simulation-based learning method in Greece. Journal of Educational Evaluation for Health Professions, 2016, 13, 13.	12.6	11
177	B-type natriuretic peptide: another brick in the wall towards better risk stratification in repaired tetralogy of Fallot: TableÂ1. Heart, 2015, 101, 416-417.	2.9	0
178	Is anemia a new cardiovascular risk factor?. International Journal of Cardiology, 2015, 186, 117-124.	1.7	62
179	The role of cardiac magnetic resonance imaging in the assessment of right ventricular function in patients with pulmonary arterial hypertension. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P364.	3.3	0
180	B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis. Stroke, 2015, 46, 1187-1195.	2.0	132

#	Article	IF	CITATIONS
181	NGAL and ST2 levels in ambulatory patients with chronic heart failure. Clinical and echocardiographic correlates. Scandinavian Cardiovascular Journal, 2015, 49, 213-219.	1.2	7
182	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	2.2	1,768
183	The Gordian knot of thromboembolism in congenital heart disease: TableÂ1. Heart, 2015, 101, 1523-1524.	2.9	19
184	Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial. Current Vascular Pharmacology, 2015, 13, 809-818.	1.7	3
185	Balloon valvuloplasty as destination therapy in elderly with severe aortic stenosis: a cardiac catheterization study. Journal of Geriatric Cardiology, 2015, 12, 218-25.	0.2	4
186	Determinants of Functional Mitral Regurgitation Severity in Patients with Ischemic Cardiomyopathy versus Nonischemic Dilated Cardiomyopathy. Echocardiography, 2014, 31, 21-28.	0.9	9
187	Threeâ€Dimensional Transesophageal Echocardiography for Guiding Percutaneous Fontan Fenestration Closure. Echocardiography, 2014, 31, E230-1.	0.9	6
188	Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review. International Journal of Cardiology, 2014, 174, 618-623.	1.7	52
189	Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. International Journal of Cardiology, 2014, 174, 360-367.	1.7	56
190	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology, 2014, 172, 115-121.	1.7	96
191	Right ventricular myxoma in a patient with tetralogy of Fallot. International Journal of Surgery Case Reports, 2014, 5, 1058-1060.	0.6	2
192	Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease. Current Pharmaceutical Design, 2014, 20, 536-544.	1.9	35
193	Cardiothoracic ratio from postero-anterior chest radiographs: A simple, reproducible and independent marker of disease severity and outcome in adults with congenital heart disease. International Journal of Cardiology, 2013, 166, 453-457.	1.7	75
194	Peak oxygen uptake correlates with disease severity and predicts outcome in adult patients with Ebstein's anomaly of the tricuspid valve. International Journal of Cardiology, 2013, 163, 305-308.	1.7	27
195	Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis. European Heart Journal Cardiovascular Imaging, 2013, 14, 425-434.	1.2	22
196	Supravalvular aortic stenosis in homozygous familial hypercholesterolemia. Hellenic Journal of Cardiology, 2013, 54, 392-3.	1.0	0
197	Total isovolumic time relates to exercise capacity in patients with transposition of the great arteries late after atrial switch procedures. Cardiology in the Young, 2012, 22, 381-389.	0.8	6
198	B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart, 2012, 98, 736-742.	2.9	87

#	Article	IF	CITATIONS
199	Heart Failure 2012. Cardiology Research and Practice, 2012, 2012, 1-3.	1.1	15
200	B-type natriuretic peptide in rheumatic diseases: A cardiac biomarker or a sophisticated acute phase reactant?. Autoimmunity Reviews, 2012, 11, 837-843.	5.8	12
201	Atrial tachyarrhythmias late after Fontan operation are related to increase in mortality and hospitalization. International Journal of Cardiology, 2012, 157, 221-226.	1.7	77
202	Percutaneous pulmonary valve implantation in the native right ventricular outflow tract. Catheterization and Cardiovascular Interventions, 2012, 79, 427-429.	1.7	7
203	Initial and Six-Year Results of Stent Implantation for Aortic Coarctation in Children. American Journal of Cardiology, 2012, 109, 1499-1503.	1.6	42
204	Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets. Current Pharmaceutical Design, 2012, 18, 1457-1464.	1.9	13
205	Exercise intolerance in patients with congenitally corrected transposition of the great arteries relates to right ventricular filling pressures. International Journal of Cardiology, 2011, 147, 219-223.	1.7	15
206	Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. International Journal of Cardiology, 2011, 149, 372-376.	1.7	69
207	Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. International Journal of Cardiology, 2011, 151, 307-312.	1.7	121
208	Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. International Journal of Cardiology, 2011, 153, 179-184.	1.7	44
209	Beneficial effect of ischemic preconditioning on post-infarction left ventricular remodeling and global left ventricular function. Cardiovascular Revascularization Medicine, 2011, 12, 286-291.	0.8	6
210	Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatology International, 2011, 31, 263-267.	3.0	37
211	Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Current Vascular Pharmacology, 2011, 9, 213-219.	1.7	7
212	Effects of renin-angiotensin system inhibition on right ventricular function in patients with mild essential hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 358-364.	1.7	11
213	Heart Failure. Cardiology Research and Practice, 2011, 2011, 1-2.	1.1	12
214	Left ventricular function in elite rowers in relation to trainingâ€induced structural myocardial adaptation. Scandinavian Journal of Medicine and Science in Sports, 2010, 20, 428-433.	2.9	15
215	Pseudohypoglycemia in a Patient With the Eisenmenger Syndrome. Annals of Internal Medicine, 2010, 152, 407.	3.9	9
216	Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clinical Rheumatology, 2010, 29, 957-964.	2.2	35

GEORGE GIANNAKOULAS

#	Article	IF	CITATIONS
217	Natriuretic Peptides in Systemic Sclerosis-related Pulmonary Arterial Hypertension. Seminars in Arthritis and Rheumatism, 2010, 39, 278-284.	3.4	23
218	Usefulness of Natriuretic Peptide Levels to Predict Mortality in Adults With Congenital Heart Disease. American Journal of Cardiology, 2010, 105, 869-873.	1.6	91
219	Usefulness of Stenting in Aortic Coarctation in Patients With the Turner Syndrome. American Journal of Cardiology, 2010, 106, 1327-1331.	1.6	14
220	Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. European Respiratory Journal, 2010, 36, 819-825.	6.7	59
221	Sinus venosus atrial septal defect in a 31-year-old female patient: a case for surgical repair. European Respiratory Review, 2010, 19, 340-344.	7.1	8
222	Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial Hypertension. Circulation, 2010, 121, 20-25.	1.6	346
223	Effects of Renin-Angiotensin System Inhibition on Left Atrial Function of Hypertensive Patients: An Echocardiographic Tissue Deformation Imaging Study. American Journal of Hypertension, 2010, 23, 556-561.	2.0	27
224	Hyponatraemia: a strong predictor of mortality in adults with congenital heart disease. European Heart Journal, 2010, 31, 595-601.	2.2	57
225	Multislice computed tomography after stent implantation for aortic coarctation. European Heart Journal, 2010, 31, 2270-2270.	2.2	2
226	Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. European Heart Journal, 2010, 31, 3073-3083.	2.2	282
227	Early Detection of Cardiac Involvement in Systemic Sclerosis Assessed by Tissue-Doppler Echocardiography: Relationship with Neurohormonal Activation and Endothelial Dysfunction. Journal of Rheumatology, 2010, 37, 993-999.	2.0	44
228	The Use of Transtelephonic Loop Recorders for the Assessment of Symptoms and Arrhythmia Recurrence After Radiofrequency Catheter Ablation. Telemedicine Journal and E-Health, 2010, 16, 792-798.	2.8	3
229	Exercise training in congenital heart disease: Should we follow the heart failure paradigm?. International Journal of Cardiology, 2010, 138, 109-111.	1.7	30
230	Heart Failure in Adults with Congenital Heart Disease. , 2010, , 59-85.		0
231	Diabetes mellitus and cerebrovascular disease: which are the actual data?. Journal of Diabetes and Its Complications, 2009, 23, 283-296.	2.3	23
232	Burden of Coronary Artery Disease in Adults With Congenital Heart Disease and Its Relation to Congenital and Traditional Heart Risk Factors. American Journal of Cardiology, 2009, 103, 1445-1450.	1.6	147
233	Left Ventricular Outflow Tract Obstruction as a Risk Factor for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 695-699.	1.6	63
234	N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatology International, 2009, 29, 347-348.	3.0	4

#	Article	IF	CITATIONS
235	Identification of high risk patients with hypertrophic cardiomyopathy in a northern Greek population. Cardiovascular Ultrasound, 2009, 7, 37.	1.6	8
236	Preparticipation cardiovascular screening in competitive athletes: the case in a Greek population. Scandinavian Journal of Medicine and Science in Sports, 2009, 19, 297-298.	2.9	1
237	Modelling in congenital heart disease. Art or science?. International Journal of Cardiology, 2009, 133, 141-144.	1.7	4
238	Structural Abnormalities of the Pulmonary Trunk in Tetralogy of Fallot and Potential Clinical Implications. Journal of the American College of Cardiology, 2009, 54, 1883-1890.	2.8	45
239	Anemia in Adults With Congenital Heart Disease Relates to Adverse Outcome. Journal of the American College of Cardiology, 2009, 54, 2093-2100.	2.8	68
240	Receptor of Advanced Glycation End Products (RAGE) Positively Regulates CD36 Expression and Reactive Oxygen Species Production in Human Monocytes in Diabetes. Angiology, 2009, 60, 772-779.	1.8	20
241	N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clinical Rheumatology, 2008, 27, 655-658.	2.2	20
242	Limitations of the findings regarding the relationship between Nâ€ŧerminal pro–brain natriuretic peptide and systemic sclerosis–related pulmonary arterial hypertension: Comment on the article by Allanore et al. Arthritis and Rheumatism, 2008, 58, 2215-2216.	6.7	3
243	Prognostic Value of Doppler-Demonstrated Left versus Biventricular Restrictive Filling Pattern in Thalassemia Major. Echocardiography, 2008, 25, 553-553.	0.9	1
244	Right Ventricular Dysfunction in Chronic Heart Failure. American Journal of Cardiology, 2008, 101, 1070.	1.6	1
245	Natriuretic peptide-guided levosimendan therapy for heart failure: A promising new approach. International Journal of Cardiology, 2008, 128, 91-93.	1.7	11
246	The Utility of the Standard 12-Lead Electrocardiogram in the Prediction of Proximal Right Coronary Artery Occlusion in Acute Inferior Myocardial Infarction. Journal of Emergency Medicine, 2008, 35, 67-72.	0.7	5
247	Time-resolved contrast-enhanced MRI in ventricular septal defect evaluation. Clinical Radiology, 2008, 63, 724-726.	1.1	0
248	Bosentan in mild pulmonary hypertension. Lancet, The, 2008, 372, 1730-1731.	13.7	4
249	Is Longitudinal Strain Associated with Left Ventricular Remodeling in Patients with Acute Myocardial Infarction?. Journal of the American Society of Echocardiography, 2008, 21, 1077.	2.8	1
250	Normal systolic function in hypertrophic cardiomyopathy: reality or myth?. European Heart Journal, 2008, 29, 948-948.	2.2	4
251	Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology, 2008, 47, 1682-1685.	1.9	44
252	Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic study. European Respiratory Journal, 2008, 31, 701-706.	6.7	44

GEORGE GIANNAKOULAS

#	Article	IF	CITATIONS
253	Right ventricular dysfunction and functional limitation in idiopathic pulmonary fibrosis. European Respiratory Journal, 2008, 31, 219-220.	6.7	3
254	Right Ventricular Function in Ischemic or Idiopathic Dilated Cardiomyopathy. Circulation Journal, 2008, 72, 238-244.	1.6	22
255	Triple type of obstruction in hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2008, 9, 1156-1158.	1.5	0
256	Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Current Opinion in Cardiology, 2008, 23, 545-554.	1.8	83
257	Diagnostic value of stored electrograms in pacemaker patients. Acta Cardiologica, 2008, 63, 59-63.	0.9	1
258	Septal alcohol ablation in hypertrophic obstructive cardiomyopathy: improving cardiac function by generating a myocardial scar. European Heart Journal, 2007, 28, 1270-1271.	2.2	2
259	Deep vein thrombosis in a patient with congenital heart disease and permanent transfemoral pacing. Europace, 2007, 9, 851-851.	1.7	0
260	Clinical Significance of Tissue Doppler Imaging in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2007, 71, 897-903.	1.6	33
261	Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. International Journal of Cardiology, 2007, 121, 135-137.	1.7	20
262	Hypertrophic cardiomyopathy involving the right ventricular apex. Canadian Journal of Cardiology, 2007, 23, 1162.	1.7	0
263	Rupture of Abdominal Aortic Aneurysms. What Matters Most: Geometry or Blood Pressure?. European Journal of Vascular and Endovascular Surgery, 2007, 34, 122.	1.5	2
264	Predictors of Left Ventricular Remodeling After Reperfused Acute Myocardial Infarction. American Journal of Cardiology, 2007, 99, 1024-1025.	1.6	12
265	Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy. Heart and Vessels, 2007, 22, 322-327.	1.2	9
266	A Struggle to SURVIVE: To Abandon or not to Abandon Levosimendan?. Cardiovascular Drugs and Therapy, 2007, 21, 401-402.	2.6	3
267	Parathyroid hormone-related protein is reduced in severe chronic heart failure. Peptides, 2006, 27, 1894-1897.	2.4	2
268	Spatial and phasic oscillation of non-Newtonian wall shear stress in human left coronary artery bifurcation: an insight to atherogenesis. Coronary Artery Disease, 2006, 17, 351-358.	0.7	59
269	Survival in Thalassaemia Major Patients Prognostic Value of Doppler-Demonstrated Left Ventricular Restrictive Filling Pattern. Circulation Journal, 2006, 70, 1037-1042.	1.6	24
270	Prevalence of Systolic Impairment in an Unselected Regional Population With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2006, 98, 1269-1272.	1.6	11

GEORGE GIANNAKOULAS

#	Article	IF	CITATIONS
271	Clinical Significance of Acute Neurohormonal Response After Levosimendan Treatment. American Journal of Cardiology, 2006, 98, 1123-1124.	1.6	15
272	Predicting the Risk of Rupture of Abdominal Aortic Aneurysms by Utilizing Various Geometrical Parameters: Revisiting the Diameter Criterion. Angiology, 2006, 57, 487-494.	1.8	73
273	Molecular Viscosity in the Normal Left Coronary Arterial Tree. Is It Related to Atherosclerosis?. Angiology, 2006, 57, 33-40.	1.8	15
274	Wall pressure gradient in normal left coronary artery tree. Medical Engineering and Physics, 2005, 27, 455-464.	1.7	34
275	Phospholamban Gene Mutations Are Not Associated with Hypertrophic Cardiomyopathy in a Northern Greek Population. Biochemical Genetics, 2005, 43, 637-642.	1.7	3
276	N-Terminal Pro-Brain Natriuretic Peptide Levels Are Elevated in Patients with Acute Ischemic Stroke. Angiology, 2005, 56, 723-730.	1.8	55
277	A computational model to predict aortic wall stresses in patients with systolic arterial hypertension. Medical Hypotheses, 2005, 65, 1191-1195.	1.5	40
278	LETTER: Multiple Malignant Gastric Stromal Tumors in a Young Female. Digestive Diseases and Sciences, 2004, 49, 1161-1164.	2.3	0
279	Acute effects of nicotine withdrawal syndrome in pilots during flight. Aviation, Space, and Environmental Medicine, 2003, 74, 247-51.	0.5	17